Monte Rosa Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 20, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 20, 2025
GLUE$10.58+0.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated balance sheets
| December 31, | December 31, | |
|---|---|---|
| (in thousands, except share and per share amounts) | 2024 | 2023 |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $224,254 | $128,101 |
| Marketable securities | 147,895 | 104,312 |
| Other receivables | 173 | 505 |
| Prepaid expenses and other current assets | 5,118 | 3,294 |
| Total current assets | 377,440 | 236,212 |
| Property and equipment, net | 29,483 | 33,803 |
| Operating lease right-of-use assets | 26,831 | 28,808 |
| Restricted cash | 4,863 | 4,580 |
| Other long-term assets | 115 | 352 |
| Total assets | $438,732 | $303,755 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $17,215 | $11,152 |
| Accrued expenses and other current liabilities | 18,785 | 14,600 |
| Current deferred revenue | 117,232 | 17,678 |
| Current portion of operating lease liability | 3,714 | 3,162 |
| Total current liabilities | 156,946 | 46,592 |
| Deferred revenue, net of current | 16,147 | 32,323 |
| Defined benefit plan liability | 3,702 | 2,713 |
| Operating lease liability, net of current | 39,001 | 42,877 |
| Total liabilities | 215,796 | 124,505 |
| Commitments and contingencies (Note 8) | ||
| Stockholders’ equity | ||
| Preferred stock, $0.0001 par value, 10,000,000 shares authorized | — | — |
| Common stock, $0.0001 par value; 500,000,000 shares authorized, 61,507,446 shares issued and outstanding as of December 31, 2024; and 50,154,929 shares issued and 50,140,233 shares outstanding as of December 31, 2023 | 6 | 5 |
| Additional paid-in capital | 664,874 | 547,857 |
| Accumulated other comprehensive loss | (3,356) | (2,724) |
| Accumulated deficit | (438,588) | (365,888) |
| Total stockholders’ equity | 222,936 | 179,250 |
| Total liabilities and stockholders’ equity | $438,732 | $303,755 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.